What Алевал Treats: Main Uses and Benefits

Aleval may be used across domains where additional symptomatic support is needed in situations involving certain distressing symptoms related to allergic processes. This application is highly relevant across conditions presenting with both acute and recurrent symptomatic discomfort.

The medication is commonly used to help with symptoms related to physical discomfort from allergic rhinitis (including seasonal and perennial forms) and Chronic Idiopathic Urticaria (long-term hives), conditions where symptoms may intensify temporarily. It is used for managing symptom clusters that may become more noticeable, such as sneezing, runny nose, nasal congestion, itchy/watery eyes, and skin itching.

“Provides supportive relief when symptoms interfere with routine activities.”

This provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

---

Quick Fact: Relief for Persistent Skin and Nasal Symptoms

Aleval is relevant in clinical settings marked by increased discomfort or tension from dermatological and respiratory allergies, and it may assist with easing common physical discomfort.

Regulatory References

1. NIH DailyMed Official Label for Levocetirizine

Eligibility Profile: Who Can and Cannot Use Алевал

The eligibility for using Алевал (levocetirizine) is determined by official regulatory bodies, primarily based on age and renal function. The medication is approved for use in Adults and Adolescents (12 years and older) and Children down to 6 months of age, with no dose adjustment required for patients with isolated hepatic impairment.

Use of Алевал is absolutely contraindicated in the following populations:

• Patients with End-Stage Renal Disease (creatinine clearance less than 10 mL/min).
• Children aged 6 months to 11 years with any degree of impaired renal function.
• Individuals with a known hypersensitivity to levocetirizine, cetirizine, or any formulation ingredient.

Conditional Use and Restrictions:

Population Group	Regulatory Status
Infants under 6 months	Safety and efficacy not established.
Older Adults	Use with caution due to potential age-related decline in kidney function.
Renal Impairment (Adults/Adolescents)	Requires restricted use with a reduced dosage schedule.
Lactating Women	Officially not recommended.
Predisposing factors for Urinary Retention	Use with caution (e.g., prostatic hyperplasia).

Interactions with other medicines and products (Official Regulatory Information)

Aleval's interaction profile, according to regulatory documents, centers on effects related to central nervous system (CNS) function and the drug’s clearance via the kidneys.

Pharmacodynamic and Substance Interactions

The co-administration of Aleval with alcohol and other CNS depressants must be avoided. This combination carries the risk of additive effects, leading to further reductions in alertness and potential impairment of CNS performance, as stated in official labeling.

Pharmacokinetic and Clearance Changes

The disposition of levocetirizine is primarily dependent on renal excretion. Co-administration with certain drugs can affect its systemic exposure:

• Ritonavir: Significantly increases the plasma Area Under the Curve (AUC) and half-life of cetirizine (the racemate) while decreasing its clearance.
• Theophylline (400 mg once daily): Causes a small, but documented, decrease (approximately 16%) in the clearance of cetirizine.

Interaction-Related Restrictions and Considerations

Official regulatory sources note that the drug is unlikely to produce or be subject to metabolic interactions via liver enzymes. However, restrictions apply based on clearance:

• Food: Does not reduce the extent of drug absorption, though it does decrease the rate of absorption.
• Severe Renal Impairment: Use is formally contraindicated in adults with end-stage renal disease (creatinine clearance less than 10 mL/min) and in children (6 months to 11 years) with any degree of impaired renal function.

Modulating beta2-Adrenoceptor Signaling

Алевал acts as an agonist that selectively targets and activates the mathbfbeta2-adrenoceptors on the surface of smooth muscle cells, initiating a specific sequence of molecular events. This engagement modulates key pathways associated with elevated physiological responses by influencing the regulation of processes driven by distinct signaling patterns.

Activating the cAMP/PKA Cascade

The activation of the beta2-adrenoceptor triggers a signal transduction cascade that involves the creation of the second messenger cyclic adenosine monophosphate (cAMP), which subsequently activates Protein Kinase A (PKA). This modification of early molecular steps engages mechanisms that alter activity within specific regulatory systems, initiating a signaling sequence that ultimately shapes systemic physiological outcomes.

Influencing Smooth Muscle Activity

The downstream effects of the cAMP/PKA cascade affect the muscle cell's contractility mechanism, primarily by altering calcium ion levels and phosphorylating key regulatory proteins. This process modifies the signaling associated with elevated physiological responses, leading to resulting physiological adjustments that facilitate a shift in pathway activity within the targeted pathways.

The administration of Aleval (levocetirizine) is standardized for oral use and is taken once daily, typically in the evening. The available dosage forms include the 5 mg film-coated tablet and an oral solution.

Standard Dosing Regimens

Population	Standard Dose	Frequency	Special Condition
Adults and Adolescents (≥ 12 years)	5 mg (Maximum daily dose)	Once Daily	May be taken with or without food.
Children (6 to 11 years)	2.5 mg	Once Daily	Dose adjustment for renal impairment applies to adolescents and adults.

The 5 mg tablet is scored to facilitate the 2.5 mg dose required for children aged 6–11 years or for dose reduction in certain adults. For younger children (6 months to 5 years), the 1.25 mg dose must be administered using the oral solution.

Dosage Adjustments and Duration

Official guidelines require mandatory dose modification for patients with impaired kidney (renal) function. Depending on the degree of impairment, the dose may be reduced to 2.5 mg daily or administered less frequently, such as every other day or twice weekly. The medication is contraindicated in individuals with end-stage renal disease (creatinine clearance less than 10 mL/min). Usage patterns range from intermittent administration for acute, time-limited symptomatic periods to continuous therapy for chronic conditions, adhering to the stated dose limits.

Research Evidence / Overview of Studies for Алевал

This overview describes the types of research and general findings related to the clinical evaluation of Алевал (levocetirizine), according to official and scientific sources. It is not intended as medical advice or a guide to personal treatment.

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The clinical evidence for the use of Алевал in conditions characterized by fluctuating or episodic manifestations like seasonal (SAR) and perennial (PAR) allergic rhinitis includes numerous short-term Randomized Controlled Trials (RCTs). These are often supplemented by systematic reviews and meta-analyses that aggregate findings from many different studies.

Research examined how outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort evolved in observed populations. Outcomes monitored included changes in Total Symptom Scores (TSS) and researchers explored changes in Health-Related Quality of Life (QoL) to examine outcomes reflecting daily functioning or activity level.

Data show patterns related to symptom measurements, which were observed in many studies comparing the active substance to placebo. Research provides context regarding short-term changes and what has been observed so far.

---

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

For conditions characterized by periods of heightened symptoms such as chronic idiopathic urticaria (long-term hives), the evidence includes placebo-controlled RCTs and clinical practice studies. This research examined outcomes linked to inflammatory or irritative states on the skin.

Studies monitored patient-reported outcomes describing perceived discomfort, specifically measuring changes in the severity of pruritus (itching) and the size and count of wheals (hives). Findings describe patterns observed in the studies, where researchers reported how symptoms evolved in the primary skin symptom scores over the defined study intervals, often four to six weeks.

---

Long-Term Research and Durability of Study Findings

Most of the primary, high-quality RCTs for Алевал observed patient responses over defined time intervals that are generally considered short-to-intermediate in duration (e.g., up to six months). These studies provide insight into short-term changes and observations related to symptom changes during periods of increased symptom activity. However, long-term effects are not fully established and there is limited information for long-term outcomes extending beyond one year. Research exploring the durability of observed findings is less characterized and often derived from observational settings, where evidence quality varies across studies.

---

Research Gaps and Areas for Further Study

A key area where evidence is limited involves the comparison of Алевал against the newest generation of available antihistamines across all measured endpoints; comparative evidence is lacking in some areas. Additionally, follow-up durations were limited in many of the core efficacy studies, meaning that long-term effects are not fully established and research is ongoing to understand continuous, years-long usage patterns.

Common questions about Алевал (FAQ)

Q: Is Алевал the same type of medicine as [similar drug name]?

A: Aleval contains levocetirizine, and according to official product information, it belongs to the pharmacological class known as selective histamine H1 receptor antagonists. This means it is a second-generation antihistamine that acts by targeting the H1 receptors in the body.

Q: Is Алевал a long-term treatment or just for short-term use?

A: Regulatory guidelines describe usage ranging from short, intermittent periods for acute symptoms to continuous therapy for chronic conditions. Regulatory documents mention an observed pattern where severe itching (pruritus) has been reported upon discontinuation of the medicine after long-term, continuous daily use.

Q: Can I stop taking Алевал suddenly if I feel better?

A: The official safety profile highlights an observed pattern where severe itching (pruritus) has been reported to occur within a few days after discontinuing the medication. This observed pattern is specifically noted in regulatory safety profiles following the cessation of long-term, continuous daily use.

Q: Are there warnings about driving or operating machinery while on Алевал?

A: Official labeling states that the medicine may cause adverse reactions such as somnolence (drowsiness) and fatigue. Due to this potential effect, official labeling indicates that caution should be exercised before engaging in activities requiring complete mental alertness, such as driving or operating machinery.

Q: Is it necessary to take Алевал at the exact same time every day?

A: The medicine is officially administered in a single intake once daily, typically recommended in the evening. The long-lasting effect of the drug supports a single daily intake to maintain steady concentrations.

Q: Can people who are pregnant or breastfeeding use Алевал?

A: Official regulatory documents address use during pregnancy by noting that the medicine is typically used only when it is clearly needed. For women who are breastfeeding, use is not recommended because the active substance is expected to pass into the breast milk.

Q: Does age affect how Алевал works in the body?

A: Studies and official information indicate that the half-life of the medicine is heavily dependent on kidney function rather than age alone. However, since older adults may experience an age-related decline in kidney function, regulatory documents state that dosage be adjusted for older adults.

Q: How long does it usually take to feel the effects of Алевал?

A: Based on pharmacokinetic studies, the drug is rapidly absorbed after being taken orally. The time it takes to reach the maximum concentration in the blood ( Tmax), which relates to the onset of action, is typically within approximately 0.8 to 1.0 hour of administration.

Q: Can Алевал be taken with common pain relievers?

A: Official regulatory documents list specific drugs (like Ritonavir and Theophylline) and CNS depressants that interact with Алевал. However, the official product information does not list common non-prescription pain relievers, such as acetaminophen or ibuprofen, as known specific pharmacokinetic or pharmacodynamic interactions.

Q: Are there any specific foods or drinks to avoid while using Алевал?

A: The official warning is against the co-administration of Aleval with alcohol and other Central Nervous System (CNS) depressants due to the risk of compounded effects. Taking the drug with food may decrease the rate at which the drug is absorbed, but it does not change the overall extent of absorption.

Q: Why does the official document list so many drug interactions for Алевал?

A: Official documentation describes the drug as being poorly metabolized by liver enzymes, with most of the substance being eliminated unchanged by the kidneys. This characteristic defines the drug's pharmacokinetic interaction profile.

Q: If I use Алевал for a long time, will my body become dependent on it?

A: Official regulatory reviews related to the medicine's classification have found that it does not have a high potential for abuse. The potential for psychic or physiological dependence was assessed and considered during the process that determined its non-prescription status in some regions.

Q: Why is Алевал sometimes described as a 'prophylactic' medicine?

A: This description aligns with the official documented use for persistent allergic rhinitis. In this case, continuous therapy may be proposed throughout the entire period of exposure to allergens, which is consistent with preventive use.

Q: How does Алевал affect my immune system?

A: The drug's mechanism of action is focused; it acts as a selective histamine H1 receptor antagonist. By targeting and inhibiting the activity of histamine, it addresses a key chemical messenger that is released by the body and drives the symptoms of an allergic response.

Q: What is the usual duration of a treatment cycle with Алевал?

A: The duration of use depends on the condition. For conditions like intermittent allergic rhinitis, official usage descriptions indicate that treatment corresponds to symptomatic periods. For persistent allergic rhinitis, the official recommendation permits continuous therapy throughout the entire anticipated period of allergen exposure.

Q: Does Алевал need a prescription?

A: The regulatory status of the medicine varies by region. In some areas, it is classified as a prescription drug, while in others, it is widely available as an over-the-counter (OTC) medicine.

Q: Is Алевал known to cause weight gain or loss?

A: According to official regulatory documents detailing clinical trial observations, weight increased is listed as an uncommon adverse reaction associated with the use of the medicine.

Q: Are there any known long-term effects of taking Алевал?

A: While research on long-term effects extending beyond one year is not fully established, the official safety profile does specifically note a risk of severe itching (pruritus) that can occur when the drug is stopped following long-term, continuous daily use.

Q: What are the symptoms of an overdose of Алевал?

A: The official overdose section describes that in adults, an overdose is generally associated with signs of Central Nervous System (CNS) depression, primarily manifesting as drowsiness. In children, initial symptoms may include agitation before progressing to drowsiness.

Storage & Disposal Map: How to Store and Dispose of Алевал — Official Regulatory Information

Storage & Disposal Scope

Requirement Type	Official Labeled Instruction
Labeled Storage Temperature	Store at Controlled Room Temperature, not to exceed 30 C (86 F).
Light/Moisture Protection	Protect from moisture and keep away from direct light.
Stability After Opening	If applicable, any reconstituted solution must be used immediately, or within the documented in-use period (e.g., 24 hours), then discarded.
Handling Requirements	Do not freeze the product. Avoid exposing the medication to excessive heat.
Packaging-Related Rules	Keep the medicine in its original container or blister packaging to maintain its protection until use.
Disposal Instructions	Dispose of unused or expired Алевал through an authorized medicine take-back program. Do not discard in household trash or flush down the toilet.
Child-Protection Storage	Keep the medicine strictly out of the sight and reach of children.

Storage/Disposal Classifications (High-Level)

Classification	Detail
Storage Condition Type	Controlled Room Temperature, Protected from Light and Moisture.
Storage-Context Constraints	Keep container sealed and intact throughout storage.

Connection to the Overall Storage/Disposal Profile Official regulatory documents define the storage constraints by setting a mandatory temperature range and prohibiting freezing, which is critical for maintaining product stability. The profile mandates that the medicine must be protected from light and moisture and kept in its original packaging. Finally, the documentation specifies that all unused product must be disposed of through controlled, authorized collection methods to prevent environmental contamination and misuse.